Developer docs
API playgroundTry for free, no card

Search company profiles

Attralus

Full company profile

uuid0000puo

Namestring
Attralus
Legal namestring
Attralus, Inc.
Websiteurl
attralus.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNaples, United States
HQ citystring
Naples
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
amyloidosis therapeutics, biopharmaceutical medicines, protein misfolding treatments, clinical-stage biotechnology, pan-amyloid removal drugs
Industry1 code
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Amyloidosis Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of pan-amyloid removal therapeutics (AT-02 and next-generation candidates) following regulatory approval. AT-02 is in Phase 1/2 trials with Phase 2 open-label extension ongoing.

attralus.com
2Diagnostic Imaging Agent Licensing
TypeLicensing Royalties
Description

Bayer acquired global rights to AT-01 (124I-evuzamitide) and AT-05 (99mTc-p5+14) imaging agents in January 2026. Financial terms not disclosed. Attralus retains focus on therapeutic development.

attralus.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Attralus is a clinical-stage biopharmaceutical company developing pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid deposits from organs and tissues in patients with systemic amyloidosis. Its lead candidate, AT-02 (zamubafusp alfa), is an IgG1 Fc-fusion biologic in Phase 2 development for AL amyloidosis. Following Bayer's January 2026 acquisition of its diagnostic imaging agents (AT-01 and AT-05), Attralus now focuses exclusively on advancing its therapeutic pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • AT-02 treatment showed mean eGFR increase of ~16 mL/min at Week 40 in AL amyloidosis patients in hematologic remission
+3 more records
Product and service1 record
1AT-02 (zamubafusp alfa)
CategoryTherapeutic Biologic
Description

AT-02 is Attralus's lead pan-amyloid removal (PAR) therapeutic — a novel IgG1 Fc-fusion biologic combining a proprietary amyloid-binding peptide with an IgG1 Fc region to target and remove toxic amyloid deposits. It is being developed for patients with AL amyloidosis and ATTR amyloidosis and is currently in a Phase 2 open-label extension study following completion of Phase 1. The FDA has granted Orphan Drug Designation for both AL and ATTR amyloidosis indications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-12
Description

Bayer acquired global rights to AT-01 (124I-evuzamitide) and AT-05 (99mTc-p5+14) pan-amyloid radiotracer imaging agents from Attralus. AT-01 is in Phase 3 for cardiac amyloidosis diagnosis with FDA Breakthrough Therapy Designation. AT-05 is in Phase 1. Bayer will advance development and commercialization of diagnostic imaging agents. Financial terms not disclosed.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Attralus

Amyloidosis Therapeuticsattralus.com

Attralus firmographics

Firmographics
Name
Attralus
Legal name
Attralus, Inc.
Website
https://attralus.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Attralus industry classification

Industry
Product category
Amyloidosis Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Amyloidosis therapeutics
  • Biopharmaceutical medicines
  • Protein misfolding treatments
  • Clinical-stage biotechnology
  • Pan-amyloid removal drugs

Where Attralus is headquartered

Location

Headquarters

HQ city
Naples
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Attralus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Therapeutic Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue expected from commercialization of pan-amyloid removal therapeutics (AT-02 and next-generation candidates) following regulatory approval. AT-02 is in Phase 1/2 trials with Phase 2 open-label extension ongoing.
  2. Diagnostic Imaging Agent Licensing: Bayer acquired global rights to AT-01 (124I-evuzamitide) and AT-05 (99mTc-p5+14) imaging agents in January 2026. Financial terms not disclosed. Attralus retains focus on therapeutic development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Attralus product offering

Product offering

Core offering

Attralus is a clinical-stage biopharmaceutical company developing pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid deposits from organs and tissues in patients with systemic amyloidosis. Its lead candidate, AT-02 (zamubafusp alfa), is an IgG1 Fc-fusion biologic in Phase 2 development for AL amyloidosis. Following Bayer's January 2026 acquisition of its diagnostic imaging agents (AT-01 and AT-05), Attralus now focuses exclusively on advancing its therapeutic pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

  • AT-02 (zamubafusp alfa) AT-02 is Attralus's lead pan-amyloid removal (PAR) therapeutic — a novel IgG1 Fc-fusion biologic combining a proprietary amyloid-binding peptide with an IgG1 Fc region to target and remove toxic amyloid deposits. It is being developed for patients with AL amyloidosis and ATTR amyloidosis and is currently in a Phase 2 open-label extension study following completion of Phase 1. The FDA has granted Orphan Drug Designation for both AL and ATTR amyloidosis indications.

Quantifiable outcome

  • AT-02 treatment showed mean eGFR increase of ~16 mL/min at Week 40 in AL amyloidosis patients in hematologic remission
  • +3 more outcomes

Companies that use Attralus

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Attralus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Attralus partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BayercoreOEM/ Whitelabel/ Licensing Partner · 12 January 2026Bayer acquired global rights to AT-01 (124I-evuzamitide) and AT-05 (99mTc-p5+14) pan-amyloid radiotracer imaging agents from Attralus. AT-01 is in Phase 3 for cardiac amyloidosis diagnosis with FDA Breakthrough Therapy Designation. AT-05 is in Phase 1. Bayer will advance development and commercialization of diagnostic imaging agents. Financial terms not disclosed.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Attralus competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Attralus social profiles

Digital presence

Attralus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Attralus leadership team

Management profile

Number of profiles

Profiles9 records

Attralus funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Attralus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Attralus

What does Attralus do?

Attralus is a clinical-stage biopharmaceutical company developing pan-amyloid removal (PAR) therapeutics that directly bind to and remove toxic amyloid deposits from organs and tissues in patients with systemic amyloidosis. Its lead candidate, AT-02 (zamubafusp alfa), is an IgG1 Fc-fusion biologic in Phase 2 development for AL amyloidosis. Following Bayer's January 2026 acquisition of its diagnostic imaging agents (AT-01 and AT-05), Attralus now focuses exclusively on advancing its therapeutic pipeline.

Is Attralus a public or private company?

Attralus is a private company. It is classified as venture growth investor backed and is currently operating.

When was Attralus founded?

Attralus was founded in 2020. It employs 11 to 50 people.

Where is Attralus based?

Attralus is headquartered in Naples, United States, in the North America region.

How does Attralus make money?

Two revenue lines are on record. Therapeutic Product Sales are the primary driver. The others are diagnostic Imaging Agent Licensing.

Does Attralus have an API?

No public API is recorded for Attralus.

What industry is Attralus in?

Attralus's product category is Amyloidosis Therapeutics. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceBayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026Bayer presented Phase III REVEAL study results for I-124 evuzamitide at ESC 2026, showing 94% sensitivity and 86% specificity for cardiac amyloidosis diagnosis. The study included 170 patients, with 55 experiencing adverse events, and no deaths occurred. Bayer plans to discuss regulatory approval with the FDA.BioSpaceInvestigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac AmyloidosisBayer announced positive topline results from the Phase III REVEAL study, which evaluated the PET/CT radiotracer I-124 evuzamitide in patients with suspected cardiac amyloidosis. The study met its primary endpoints of sensitivity and specificity for diagnosis based on visual scan interpretation. Bayer plans to discuss regulatory approval with the FDA and other authorities.Business Wire BlogInvestigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac AmyloidosisBayer announced positive topline results from the Phase III REVEAL study, which evaluated the PET/CT radiotracer I-124 evuzamitide in patients with suspected cardiac amyloidosis. The study met its primary endpoints of sensitivity and specificity for diagnosis based on visual scan interpretation. Bayer plans to discuss regulatory approval with the FDA and other authorities.openPR.comAL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsightDelveInsight's AL Amyloidosis Pipeline 2026 report documents the therapeutic development landscape for this rare disease, with over 10 companies developing 10+ treatment therapies. Key clinical milestones include Immix Biopharma completing enrollment for its NXC-201 CAR-T therapy Phase II trial in March 2026 and receiving FDA RMAT designation in February 2025, while AstraZeneca's anselamimab failed to meet primary endpoints in two Phase III trials in July 2025. Prothena subsequently discontinued birtamimab development in May 2025 following its Phase 3 AFFIRM-AL trial failure, and Attralus initiated enrollment for its Phase 3 REVEAL diagnostic imaging study in January 2025.Signify ResearchMedical Imaging Market Update 2026: MRI Innovation, CT AI Advances & Molecular Imaging MomentumSignify Research's February 2026 newsletter covers multiple developments across MRI, CT, and Molecular Imaging markets, including Siemens Healthineers receiving FDA clearance for a helium-free 1.5T MRI system and Aidoc securing FDA clearance for the first comprehensive AI triage solution for CT scans. Bruker signed $500 million in multiyear contracts for MRI magnet supply while 4DMedical raised over $100 million to expand its functional CT software in the US market. In Molecular Imaging, GE HealthCare faces a recall of Omni Legend PET systems due to a software glitch, Bayer expanded its portfolio through acquiring two imaging agents from Attralus, and Lantheus completed the divestment of its SPECT business to Shine Technologies.FierceBiotechBayer boosts imaging portfolio with Attralus deal for 2 diagnostic tracersBayer has entered into an agreement to acquire two experimental imaging agents, AT-01 and AT-05, from Florida-based Attralus, marking the German pharma company's entry into the diagnostic tracers development space. AT-01 is a PET tracer currently in phase 3 testing and holds FDA breakthrough designation for cardiac amyloidosis, while AT-05 is a SPECT tracer in phase 1 testing. Bayer estimated the global market for radio-diagnostic tracers was worth approximately $3 billion in 2024 and projected to grow significantly in coming years.GlobeNewswireAttralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and ExpositionAttralus, Inc. announced it will present Phase 1/2 clinical trial data on AT-02, its pan-amyloid removal therapeutic candidate, at the 67th ASH Annual Meeting in Orlando, Florida on December 6-9, 2025. The study showed that AL amyloidosis patients in hematological remission who received AT-02 (2.5 gm q2w) for 40 weeks demonstrated improved renal function with a mean eGFR increase of approximately 16 mL/min, with 83% of participants showing eGFR improvement from baseline. AL amyloidosis affects approximately 25,000 patients in the US with no approved therapies targeting existing amyloid removal, representing a significant unmet medical need.SecSEC FORM DAttralus, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of securities under Rule 506(b), initiated on January 26, 2024. The biotechnology company raised approximately $56 million from 12 investors in this equity offering. This regulatory filing discloses the financial terms and key executive officers involved in the capital raise.GlobeNewswireAttralus Closes $56 Million FinancingAttralus, Inc. has closed a $56 million financing round led by Alpha Wave Global, with participation from Bristol Myers Squibb and other existing investors. The company intends to use the proceeds to advance its clinical pipeline, specifically the Phase 1/2 development of its lead therapeutic candidate AT-02 for systemic amyloidosis.